Page last updated: 2024-10-15

technetium tc 99m-ethylenedicysteine

Description

technetium Tc 99m-ethylenedicysteine: renal imaging agent; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID155491280
MeSH IDM0199438

Synonyms (8)

Synonym
technetium tc 99m-ethylenedicysteine
154069-62-2
technetium tc 99m ethylenedicysteine
2d30ph7dw4 ,
technetium (99mtc)-l,l-ethylenedicysteine [who-dd]
technetium tc-99m ethylenedicysteine
technetate(2-)-99tc, ((n,n'-1,2-ethanediylbis(l-cysteinato-.kappa.n,.kappa.s))(5-))oxo-, dihydrogen, (sp-5-35)-
technetate(2-)-99tc, ((n,n'-1,2-ethanediylbis(l-cysteinato))(5-)-n,n',s,s')oxo-, dihydrogen, (sp-5-35)-

Toxicity

ExcerptReference
" In this study, we investigated the toxic effects of ifosfamide and cisplatin by clinical and biochemical parameters in relation to (99m)Tc-dimercaptosuccinic acid ((99m)Tc-DMSA) and Tc(99m)N, N-ethylenedicysteine (EC) renal scintigraphy."( The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity.
Akyuz, C; Caglar, M; Yarís, N, 2001
)

Pharmacokinetics

ExcerptReference
" The images and renogram parameters, that is TMAX and T1/2 of both the agents, were similar in all the subjects."( A comparison of single plasma sample methods to estimate renal clearance using 99mTc-ethylenedicysteine and 99mTc-mercaptoacetyltriglycine.
Afshan, A; Rafique, A; Saeed, S; Sohaib, M, 2013
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (66)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's30 (45.45)18.2507
2000's22 (33.33)29.6817
2010's13 (19.70)24.3611
2020's1 (1.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (18.31%)5.53%
Reviews2 (2.82%)6.00%
Case Studies10 (14.08%)4.05%
Observational0 (0.00%)0.25%
Other46 (64.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Screening Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma[NCT01689766]Phase 2150 participants (Actual)Interventional2003-11-30Completed
A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors[NCT01689727]Phase 240 participants (Actual)Interventional2002-09-30Completed
A MULTI-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FOLATESCAN (TECHNETIUM Tc 99m EC20) IN PATIENTS WITH SUSPECTED OVARIAN CARCINOMA OR RECURRENT ENDOMETRIAL CARCINOMA[NCT01689714]Phase 216 participants (Actual)Interventional2003-08-31Completed
A Multi-center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma[NCT01689662]Phase 240 participants (Actual)Interventional2002-08-31Completed
CLINICAL STUDY OF A SINGLE-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND BIODISTRIBUTION OF TECHNETIUM Tc 99m EC20 IN NORMAL VOLUNTEERS AND OVARIAN CANCER PATIENTS[NCT01689636]Phase 18 participants (Actual)Interventional2000-08-31Completed
A Multi-center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer[NCT01686256]Phase 112 participants (Actual)Interventional2001-08-31Completed
A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor[NCT01684098]Phase 240 participants Interventional2003-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]